A Comparison of Clinicopathological Characteristics and Short-Term Outcome of Papillary Thyroid Carcinoma with Tall Cell Histology and Classic Papillary Thyroid Carcinoma: A Single-Institution Experience

Geethalakshmi Sampathkumar, Vasantha Nair, Usha V. Menon, N. V. Smitha¹, Shanmuga Sundaram², Harish Kumar, Praveen V. Pavithran, Nisha Bhavani, Arun S. Menon, Nithya Abraham, Annie Pullikkal
Departments of Endocrinology, ¹Pathology and ²Nuclear Medicine, Amrita Institute of Medical Sciences and Research Centre, Cochin, Kerala, India

Abstract

Context: Papillary thyroid carcinoma with tall cell histology (PTC-TCH) is an aggressive subtype in terms of clinicopathological features and outcome. Even 10% of tall cells can show aggressive features. Aims: The aim of this study is to investigate the behavior of PTC-TCH, to compare with classic PTC (cPTC), and evaluate the short-term outcome. Settings and Design: This is a retrospective analysis of patients with cPTC and those with TCH (PTC-TCH) seen from January 2010 to May 2017 seen in our Thyroid Cancer Clinic. Materials and Methods: A total of 40 patients with TCH were compared with 352 cPTC and evaluated for age, gender, tumor size, presence of multifocality, capsular, vascular invasion, extrathyroid extension, and appearance of metastases. Short-term response to therapy was assessed using the 2015 American Thyroid Association guidelines. Statistical Analysis: \(P < 0.05\) was considered statistically significant. Results: PTC with TCH presented at a younger age, had larger tumors, and more extrathyroid extension. Seven out of 40 cases developed lung metastases, (17.5% vs. 4.5% in cPTC), within a year of diagnosis. Conclusion: PTC-TCH irrespective of percentage of tall cells showed aggressive features and early metastases. They should be recognized early as an aggressive subtype and treated intensively. Close follow-up must be instituted to look for metastases, especially to the lungs.

Keywords: Differentiated thyroid carcinoma, lung metastasis, papillary thyroid carcinoma with tall cell histology, prevalence

INTRODUCTION

Tall cell variant of papillary thyroid carcinoma (TCV-PTC) was first recognized in 1976.[1] Recently, it has gained attention because of its aggressive nature in terms of pathological characteristics and patient outcome.[2] In addition, 24% of deaths from thyroid cancer is attributed to TCV-PTC, being second only to poorly differentiated thyroid carcinoma (DTC).[3] The American Thyroid Association (ATA) places it in the intermediate risk in terms of recurrence.[4] Controversy exists in the definition. It is not clear whether the percentage of tall cells influence the outcome. There have been reports where even 10% tall cells have shown poor prognosis (tall cell features) similar to those with >50% tall cells (TCV).[5]

Objectives

At our institute, we have begun to see increasing numbers of thyroid cancer, mainly PTC and also tall cell histology (TCH), we undertook a study to evaluate the prevalence, characteristics, and outcome of these cases compared with classic PTC (cPTC) and also whether the percentage of tall cells influence the prognosis.

Address for correspondence: Dr. Geethalakshmi Sampathkumar, Amrita Institute of Medical Sciences and Research Centre, AIMS Ponekkara PO, Cochin - 682 041, Kerala, India. E-mail: drgeethalakshmi86@gmail.com

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: reprints@medknow.com

How to cite this article: Sampathkumar G, Nair V, Menon UV, Smitha NV, Sundaram S, Kumar H, et al. A Comparison of clinicopathological characteristics and short-term outcome of papillary thyroid carcinoma with tall cell histology and classic papillary thyroid carcinoma: A single-institution experience. Indian J Endocr Metab 2018;22:405-9.
**Materials and Methods**

This study evaluated the prevalence, clinicopathological characteristics, and short-term outcome in patients with PTC with TCH. Clinicopathological features were compared with cPTC for any significant differences. In addition, although small in numbers, we compared those with >50% tall cells and those with <50%, to see if they differed in any of the variables studied. We also analyzed the few cases which developed lung metastases.

**Amrita institute thyroid carcinoma database**

The Thyroid Cancer Clinic was setup at our institute in January 2010. Patients seen there were consecutively entered into a database. From the outset, the management was based on the ATA guidelines published in 2009.[4] After initial surgery and radioactive iodine (RAI) ablation, all patients were begun on appropriate suppressive doses of thyroxine. Six months later, they underwent a diagnostic whole-body scan, ultrasonography of the neck, stimulated thyroglobulin (Tg), and Tg antibody (TgAb) when thyroid-stimulating hormone was above 30. When indicated, they were given RAI ablation. Accordingly, they were classified into low-, intermediate-, and high-risk categories for recurrence (ATA, 2009). The follow-up initially used the response to therapy categories outlined by Tuttle and Leboeuf[8] later modified according to the ATA 2015 recommendations.

Data from January 2010 to May 2017 were collected. At the time of data collection, our database contained 742 consecutive patients with DTC. We excluded all other variants of PTC, micro-PTC (MPTC), follicular, Hurthle cell, anaplastic, poorly differentiated types (ATC and PDTC), and children with PTC. The remaining 392 patients formed subjects of this study. Clinical and histopathological information were obtained from the electronic medical records.

A tumor was defined as TCV if it contained >50% tall cells. Tall cells were defined as those cells with a height greater than thrice its width, eosinophilic cytoplasm, and basilar-oriented nuclei besides the classic nuclear features of PTC. Both definitions for PTC and tall cell description were as recommended by the World Health Organization (WHO) Classification of Tumors (2004) and endorsed by the ATA guidelines in 2015 till modified recently. There were 352 patients with cPTC and 40 with TCV. We categorized these 40 patients (tall cells >10%) as TCH (PTC-TCH) [Figure 1]. Patients with <10% tall cells were excluded. These 40 patients were then subdivided into TCV (TCV-PTC) when tall cells were >50% (n = 22) and PTC with tall cell features or TCF-PTC (n = 18) with 10%–50% tall cells.

The following data were collected: age at diagnosis, presenting features, type of surgery performed (including reexploration of the neck), Tg, and TgAb levels serially and at the time of response to therapy evaluation and frequency of RAI therapy. Out of the 40 histopathology specimens/slides, 32 were read by a senior head-and-neck oncopathologist, 4 reported by another senior pathologist, and 4 were unfortunately operated in other hospitals. Histopathology reporting was based on the Royal College of Pathologists (RC Path)[9] and the College of American Pathologists (CAP) format.[8]

The following histopathological parameters were assessed: tumor size, multifocality, vascular invasion, perineural infiltration, microscopic extrathyroidal extension (ETE) (into perithyroidal soft tissue), and presence of metastatic lymph nodes. Microscopic ETE was defined based on the RC Path/CAP guidelines. Lymph nodes were noted as positive on the basis of original histopathology reports or if they appeared in the reexplored tissue.

**Assays**

Tg level was determined by the electrochemiluminescence assay (Elecsys 2010), Roche, Switzerland. The first-generation kit used in the initial 5 years had a limit of detection (LOD) of <0.1 ng/ml. From 2015, the second-generation kit used in testing had a LOD of <0.040 and reference range of 0.04–500 ng/ml. TgAb was assessed using the ARCHITECT anti-Tg assay (Abbott, United States), a chemiluminescent microparticle 2-step immunoassay which quantifies the IgG class of TgAb in human serum and plasma on the ARCHITECT System. The lower LOD was 1.0 IU/mL. Reference range is 0.0–4.11 IU/mL. The lowest level exhibiting a 20% CV is 0.31 IU/mL.

**Statistical analysis**

Nonparametric statistics were used to compare the continuous variables. Continuous variables are reported as a mean ± standard deviation or median values and ranges, while categorical variables are reported as absolute numbers and percentages. Multivariate regression analysis was done to assess the effect of the various parameters associated with PTC-TCH. P < 0.05 was considered statistically significant. All analyses were performed with IBM SPSS software (Version 21.0, Chicago, IL, USA).
Results
Out of 392 patients included, 352 were cPTC and 40 PTC-TCH. Baseline features of PTC-TCH were as follows: the mean age at diagnosis was 42.9 years (range 23–71) with 52.5% females. About 62.5% of patients were <45 years of age. The mean tumor size was 30.3 mm (±16.1 mm). When we compared the pathological features of cPTC and PTC-TCH, we found that tall cell tumors were larger than cPTC (30.3 mm vs. 18.2 mm, \( P = 0.001 \)) [Figure 1]. The two groups were not statistically different in terms of age at presentation (42.9 years vs. 43.1 years, \( P = 0.886 \)) and duration of neck swelling (20.73 vs. 21.8 months, \( P = 0.861 \)). There was a male predilection for tall cell tumors (47.5% vs. 33.5%, \( P = 0.081 \)). Tall cell tumors had more of statistically significant \(( P < 0.05)\) capsular invasion (54.1% vs. 37.7%, \( P = 0.270 \)), ETE (55% vs. 30.4%, \( P = 0.224 \)), and distant metastasis (20% vs. 6.5%, \( P = 0.751 \) (predominantly lung metastasis – 17.5% vs. 4.5%, \( P = 0.477 \)) when compared to cPTC [Figure 2]. Tall cell tumors were more often multifocal (57.9% vs. 47%, \( P = 0.443 \)), had slightly more association with lymphocytic thyroiditis (48.4% vs. 44.7%, \( P = 0.973 \)), more lymph nodal metastasis (25% vs. 14%, \( P = 0.795 \)) with perinodal spread (36.8% vs. 21.2%, \( P = 0.312 \)). However, these differences were not statistically significant. Vascular invasion was unusually lower in tall cell group than cPTC (24.3% vs. 29.8%, \( P = 0.142 \)). Furthermore, multivariate analysis showed a significant correlation between PTC-TCH and lung metastasis (\( P = 0.004 \)).

We compared the two groups: TCV-PTC (>50% tall cells) and TCF-PTC (10%–50% tall cells) for any difference in behavior. However, the two groups were not statistically different in terms of clinical or histopathological characteristics (\( P > 0.05 \)) [Table 1].

Follow-up and response to therapy
The mean duration of follow-up was 1.6 years. Out of those with follow-up >6 months, 72% have an incomplete/indeterminate response to therapy at their last follow-up. Surprisingly, more patients in focal tall cell group had incomplete/indeterminate response compared to TCV.

Discussion
To the best of our knowledge, there has been no publication on TCH-PTC from India so far. In a review from Chennai, India, which analyzed the types of PTC, only one out of 377 patients belonged to TCV-PTC.\(^{[9]}\) A meta-analysis on TCV-PTC by Liu et al.\(^{[10]}\) in 2017 found only a few Asian studies from Korea and China and none from India.

Prevalence of TCH among PTC in our study was 10.2%, comparable with other published reports. Our prevalence was much higher than reported in the Chennai study and more in keeping with the Western and South Asian data. ATA guidelines report a 1.3%–13.3% prevalence for TCV-PTC.\(^{[9]}\) The wide range is due to the use of varying criteria (tall cell percentage).

The median follow-up for TCH-PTC was 12 months (range 1–5 years).
Short-term outcome in our series was similar between TCV-PTC and TCF-PTC. Out of the 15 patients with TCV-PTC, six had excellent response, whereas nine had incomplete response. TCF-PTC group did not behave differently in this aspect (excellent – 3 and incomplete – 11). These results suggest that percent tall cells do not influence the prognosis.

Metastasis from PTC is uncommon as these tumors have an indolent course. The most common metastatic site is lungs followed by bone and other organs. Certainly, none of the large series reporting lung metastasis from PTC recently looked at the contribution among them from TCF/TCV.[12,13]

In our series, seven out of 40 (17.5%) showed lung metastases, significantly higher than in cPTC [Table 2]. These were documented by the first diagnostic/posttherapy iodine scan [Figure 4], chest CT, or PET/CT. Histopathological confirmation was available in only one patient who developed lobar collapse and underwent lobectomy. As noted in our study, Kazaure et al.[11] reported distant metastases from PTC to be 4.3% as against 11.1% from TCV. Machens et al.[14] reported a 4.8% prevalence of TCV, of which 31% had distant metastasis, predominantly pulmonary. The authors pointed out the high incidence and cautioned the need for close follow-up in these cases.

In our patients, the unusual feature was the appearance of lung lesions at diagnosis in two cases and within 1 year of detection of the primary in the rest. Ghossein et al.[15] had reported 7 distant metastases in 62 TCV patients, out of which four were to the lungs, noted after 3 years of follow-up (3.4, 10.6, and 14.6 years). In a Saudi Arabia study[16] on TCV-PTC defined as >10% tall cells, distant metastasis was seen in 8 out of 42 patients with TCV comparable with ours. Lung involvement was 11.9% much lower than ours. Male preponderance was noted (six out of seven) in our cases of lung metastases.

Although all our cases were ablated with RAI except one patient, all needed a second dose of RAI for persistent disease. Of these, three belonged to the TCV group and four were in the TCF group. Three of our patients required reexploration for local recurrence. These observations point to the intrinsic aggressive behavior of PTC-TCH, perhaps irrespective of tall cell percentage.

Many mechanisms are postulated to explain the aggressive nature of TCV. TERT promoter mutations (TERTp) are prevalent in TCV more than in cPTC (30% vs. 10%).[17] These mutations have been associated with recurrence of PTC and may even contribute to mortality.[18] It is possible that these mutations account for the aggressive behavior of these tumors. We feel that it would be worthwhile looking for TERTp in TCH-PTC.

**Table 2: Characteristics of papillary thyroid carcinoma-tall cell histology with lung metastasis (n=7)**

| Characteristics | Mean       |
|-----------------|------------|
| Tumor size      | 3.3 (cm)   |
| Age at presentation (years) |   |
| >45             | 3          |
| <45             | 4          |
| Gender          |            |
| Males           | 5          |
| Females         | 2          |
| Multifocal      | 3          |
| Lymphocytic thyroiditis | 1         |
| ETE             | 5          |
| Capsular invasion | 3         |
| Vascular invasion | 1         |
| >5 lymph nodes  | 3          |
| ETE: Extrathyroidal extension |

Shortcomings of our study include small numbers of TCH-PTC and short duration of follow-up. We could not use the new WHO definition (TCV-tall cells >30%) in this study as it became available only recently. Our advantage is the unique nature of the database and uniformity in management using the international standards. This feature adds to the credibility of our data. Our numbers are small to come to strong conclusions. Our results, however, do support the view that TCH-PTC is an aggressive subtype. The lack of importance for percent tall cells in the histology is
ConclusioN

We also suggest that TCV, irrespective of the percent tall cells, should be moved into high-risk category of the ATA risk stratification so that it receives initial aggressive therapy and close follow-up for recurrence either at locoregional sites or in distant organs, especially the lungs. In this context, we welcome the change in the definition of TCV to those having >30% of tall cells in the new edition of WHO classification of tumors. More studies in the future should evaluate the contribution of 10%–30% tall cells in determining the prognosis.

Acknowledgment

We would like to thank the Thyroid Cancer Care Team of our institution.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

References

1. Hawk WA, Hazard JB. The many appearances of papillary carcinoma of the thyroid. Cleve Clin Q 1976;43:207-15.
2. Gunly I, Ibrahimpasic T, Rivera M, Nixon I, Palmer F, Patel SG, et al. Prognostic implications of papillary thyroid carcinoma with tall-cell features. Thyroid 2014;24:662-70.
3. Xu B, Ibrahimpasic T, Wang L, Sabra MM, Migliacci JC, Tuttle RM, et al. Clinicopathologic features of fatal non-anaplastic follicular cell-derived thyroid carcinomas. Thyroid 2016;26:1588-97.
4. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009;19:1167-214.
5. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 2016;26:1-33.
6. Tuttle RM, Leboeuf R. Follow up approaches in thyroid cancer: A risk adapted paradigm. Endocrinol Metab Clin North Am 2008;37:419-35, ix-x.
7. Stephenson J. Standards and Datasets for Reporting Cancers Dataset for Thyroid Cancer Histopathology Reports; February, 2014. Available from: https://www.cap.org/apps/docs/committees/cancer/cancer_protocols/2014/Thyroid_14Protocol_3100.pdf. [Last accessed on 2018 Feb 20].
8. Seethala RR, Asa SL, Carty SE, Hodak SP, McHugh JB, Richardson MS, et al. Protocol for the Examination of Specimens from Patients With Carcinomas of the Thyroid Gland. Northfield, IL: College of American Pathologists; August, 2014. Available from: http://www.cap.org/apps/docs/committees/cancer/cancer_protocols/2014/Thyroid_14Protocol_3100.pdf. [Last accessed on 2018 Feb 20].
9. Karkuzhali P, Yogambal M, Kumar M. An Indian tertiary care hospital scenario of papillary carcinoma of thyroid. J Clin Diagn Res 2017;11:EC26-9.
10. Liu Z, Zeng W, Chen T, Guo Y, Zhang C, Liu C, et al. A comparison of the clinicopathological features and prognoses of the classical and the tall cell variant of papillary thyroid cancer: A meta-analysis. Oncotarget 2017;8:6222-32.
11. Kazaura HS, Roman SA, Sosa JA. Aggressive variants of papillary thyroid cancer: Incidence, characteristics and predictors of survival among 43,738 patients. Ann Surg Oncol 2012;19:1874-80.
12. Wang R, Zhang Y, Tan J, Zhang G, Zhang R, Zheng W, et al. Analysis of radioiodine therapy and prognostic factors of differentiated thyroid cancer patients with pulmonary metastasis: An 8-year retrospective study. Medicine (Baltimore) 2017;96:e6809.
13. Song HJ, Qiu ZL, Shen CT, Wei WJ, Luo QY. Pulmonary metastases in differentiated thyroid cancer: Efficacy of radioiodine therapy and prognostic factors. Eur J Endocrinol 2015;173:399-408.
14. Machens A, Holzhausen HJ, Lautenschläger C, Dralle H. The tall-cell variant of papillary thyroid carcinoma: A multivariate analysis of clinical risk factors. Langenbecks Arch Surg 2004;389:278-82.
15. Ghossein RA, Leboeuf R, Patel KN, Rivera M, Katabi N, Carlson DL, et al. Tall cell variant of papillary thyroid carcinoma without extrathyroid extension: Biologic behavior and clinical implications. Thyroid 2007;17:655-61.
16. Al-Qahtani KH, Tunio MA, Al Asiri M, Bayoumi Y, Alshehri WA, Aljohani NJ, et al. Tall cell variant papillary thyroid carcinoma in Saudi patients: A clinicopathological and outcomes analysis. Saudi Med J 2017;38:1220-4.
17. Liu X, Bishop J, Shan Y, Pai S, Liu D, Murugan AK, et al. Highly prevalent TERT promoter mutations in aggressive thyroid cancers. Endocr Relat Cancer 2013;20:603-10.
18. Liu C, Liu Z, Chen T, Zeng W, Guo Y, Huang T, et al. TERT promoter mutation and its association with clinicopathological features and prognosis of papillary thyroid cancer: A meta-analysis. Sci Rep 2016;6:36990.